Use of Recombinant Factor VIla (NovoSeven®) in the Treatment of Two Patients with Type III von Willebrand’s Disease and an inhibitor against von Willebrand Factor
Type III von Willebrand’s disease (vWD) is the most severe form of this inherited coag-ulopathy. It is characterized by a defective primary hemostasis, a prolonged bleeding time and a reduced plasma factor VIII/von Willebrand factor (FVIII/vWF) complex and ristocetin cofactor (Rad). Patients affe...